-
Something wrong with this record ?
Implementation of mechanism of action biology-driven early drug development for children with cancer
AD. Pearson, R. Herold, R. Rousseau, C. Copland, B. Bradley-Garelik, D. Binner, R. Capdeville, H. Caron, J. Carleer, L. Chesler, B. Geoerger, P. Kearns, LV. Marshall, SM. Pfister, G. Schleiermacher, J. Skolnik, C. Spadoni, J. Sterba, H. van den...
Language English Country England, Great Britain
Document type Journal Article, Review
- MeSH
- Molecular Targeted Therapy methods MeSH
- Databases, Factual MeSH
- Child MeSH
- Drug Industry methods MeSH
- Drug Evaluation MeSH
- Medical Oncology methods MeSH
- Humans MeSH
- Neoplasms drug therapy MeSH
- Drug Discovery methods MeSH
- Antineoplastic Agents therapeutic use MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
An urgent need remains for new paediatric oncology drugs to cure children who die from cancer and to reduce drug-related sequelae in survivors. In 2007, the European Paediatric Regulation came into law requiring industry to create paediatric drug (all types of medicinal products) development programmes alongside those for adults. Unfortunately, paediatric drug development is still largely centred on adult conditions and not a mechanism of action (MoA)-based model, even though this would be more logical for childhood tumours as these have much fewer non-synonymous coding mutations than adult malignancies. Recent large-scale sequencing by International Genome Consortium and Paediatric Cancer Genome Project has further shown that the genetic and epigenetic repertoire of driver mutations in specific childhood malignancies differs from more common adult-type malignancies. To bring about much needed change, a Paediatric Platform, ACCELERATE, was proposed in 2013 by the Cancer Drug Development Forum, Innovative Therapies for Children with Cancer, the European Network for Cancer Research in Children and Adolescents and the European Society for Paediatric Oncology. The Platform, comprising multiple stakeholders in paediatric oncology, has three working groups, one with responsibility for promoting and developing high-quality MoA-informed paediatric drug development programmes, including specific measures for adolescents. Key is the establishment of a freely accessible aggregated database of paediatric biological tumour drug targets to be aligned with an aggregated pipeline of drugs. This will enable prioritisation and conduct of early phase clinical paediatric trials to evaluate these drugs against promising therapeutic targets and to generate clinical paediatric efficacy and safety data in an accelerated time frame. Through this work, the Platform seeks to ensure that potentially effective drugs, where the MoA is known and thought to be relevant to paediatric malignancies, are evaluated in early phase clinical trials, and that this approach to generate pre-clinical and clinical data is systematically pursued by academia, sponsors, industry, and regulatory bodies to bring new paediatric oncology drugs to front-line therapy more rapidly.
Belgian Federal Agency for Medicines and Health Products Brussels Belgium
Bristol Myers Squibb 5 Research Parkway Wallingford CT 06492 USA
Centre for English Language Teaching University of York UK
Children and Young People's Unit The Royal Marsden NHS Foundation Trust Sutton Surrey UK
Clinical Cooperation Unit Pediatric Oncology Heidelberg Germany
Create for Chloe and UK representative for aPODD UK
Department of Clinical Research Institut Gustave Roussy Paris Sud University Paris France
Department of Pediatric and Adolescent Oncology Gustave Roussy France
Division of Clinical Studies The Institute of Cancer Research London UK
Genentech Inc 1 DNA Way South San Francisco CA 94080 USA
German Cancer Research Center and Heidelberg University Hospital Heidelberg 69120 Germany
Hoffman La Roche Basel Switzerland
Novartis Pharma AG Basel CH 4002 Switzerland
Paediatric Haematology Oncology Unit Antwerp University Hospital Antwerp University Belgium
Product Development Scientific Support Department European Medicines Agency Canary Wharf London UK
TetraLogic Pharmaceuticals Malvern PA 19355 USA
The Institute of Cancer Research The Royal Marsden NHS Foundation Trust Sutton London UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031689
- 003
- CZ-PrNML
- 005
- 20171025115554.0
- 007
- ta
- 008
- 171025s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2016.04.001 $2 doi
- 035 __
- $a (PubMed)27258969
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Pearson, Andrew D J $u The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, London, UK. Electronic address: andy1pearson@btinternet.com.
- 245 10
- $a Implementation of mechanism of action biology-driven early drug development for children with cancer / $c AD. Pearson, R. Herold, R. Rousseau, C. Copland, B. Bradley-Garelik, D. Binner, R. Capdeville, H. Caron, J. Carleer, L. Chesler, B. Geoerger, P. Kearns, LV. Marshall, SM. Pfister, G. Schleiermacher, J. Skolnik, C. Spadoni, J. Sterba, H. van den Berg, M. Uttenreuther-Fischer, O. Witt, K. Norga, G. Vassal, . ,
- 520 9_
- $a An urgent need remains for new paediatric oncology drugs to cure children who die from cancer and to reduce drug-related sequelae in survivors. In 2007, the European Paediatric Regulation came into law requiring industry to create paediatric drug (all types of medicinal products) development programmes alongside those for adults. Unfortunately, paediatric drug development is still largely centred on adult conditions and not a mechanism of action (MoA)-based model, even though this would be more logical for childhood tumours as these have much fewer non-synonymous coding mutations than adult malignancies. Recent large-scale sequencing by International Genome Consortium and Paediatric Cancer Genome Project has further shown that the genetic and epigenetic repertoire of driver mutations in specific childhood malignancies differs from more common adult-type malignancies. To bring about much needed change, a Paediatric Platform, ACCELERATE, was proposed in 2013 by the Cancer Drug Development Forum, Innovative Therapies for Children with Cancer, the European Network for Cancer Research in Children and Adolescents and the European Society for Paediatric Oncology. The Platform, comprising multiple stakeholders in paediatric oncology, has three working groups, one with responsibility for promoting and developing high-quality MoA-informed paediatric drug development programmes, including specific measures for adolescents. Key is the establishment of a freely accessible aggregated database of paediatric biological tumour drug targets to be aligned with an aggregated pipeline of drugs. This will enable prioritisation and conduct of early phase clinical paediatric trials to evaluate these drugs against promising therapeutic targets and to generate clinical paediatric efficacy and safety data in an accelerated time frame. Through this work, the Platform seeks to ensure that potentially effective drugs, where the MoA is known and thought to be relevant to paediatric malignancies, are evaluated in early phase clinical trials, and that this approach to generate pre-clinical and clinical data is systematically pursued by academia, sponsors, industry, and regulatory bodies to bring new paediatric oncology drugs to front-line therapy more rapidly.
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a databáze faktografické $7 D016208
- 650 _2
- $a objevování léků $x metody $7 D055808
- 650 _2
- $a hodnocení léčiv $7 D004341
- 650 _2
- $a farmaceutický průmysl $x metody $7 D004345
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lékařská onkologie $x metody $7 D008495
- 650 _2
- $a cílená molekulární terapie $x metody $7 D058990
- 650 _2
- $a nádory $x farmakoterapie $7 D009369
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Herold, Ralf $u Product Development Scientific Support Department, European Medicines Agency, Canary Wharf, London, UK.
- 700 1_
- $a Rousseau, Raphaël $u Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
- 700 1_
- $a Copland, Chris $u Centre for English Language Teaching, University of York, UK.
- 700 1_
- $a Bradley-Garelik, Brigid $u Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA.
- 700 1_
- $a Binner, Debbie $u Create for Chloe and UK representative for aPODD, UK.
- 700 1_
- $a Capdeville, Renaud $u Novartis Pharma AG, Basel CH-4002, Switzerland.
- 700 1_
- $a Caron, Hubert $u Hoffman-La Roche, Basel, Switzerland; Department of Pediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam, The Netherlands.
- 700 1_
- $a Carleer, Jacqueline $u Belgian Federal Agency for Medicines and Health Products, Brussels, Belgium.
- 700 1_
- $a Chesler, Louis $u Division of Clinical Studies, The Institute of Cancer Research, London, UK.
- 700 1_
- $a Geoerger, Birgit $u Department of Pediatric and Adolescent Oncology, Gustave Roussy, France.
- 700 1_
- $a Kearns, Pamela $u Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
- 700 1_
- $a Marshall, Lynley V $u The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, London, UK; Children and Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.
- 700 1_
- $a Pfister, Stefan M $u German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), and Heidelberg University Hospital, Heidelberg 69120, Germany.
- 700 1_
- $a Schleiermacher, Gudrun $u U830 INSERM, Recherche Translationelle en Oncologie Pédiatrique (RTOP) and Department of Pediatric Oncology, Institut Curie, Paris, France.
- 700 1_
- $a Skolnik, Jeffrey $u TetraLogic Pharmaceuticals, Malvern, PA 19355, USA.
- 700 1_
- $a Spadoni, Cesare $u aPODD Foundation, London, UK.
- 700 1_
- $a Sterba, Jaroslav $u Department of Paediatric Oncology, Faculty of Medicine, University Hospital Brno and Masaryk University, Brno, Czech Republic; Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, ICRC Brno, Brno, Czech Republic.
- 700 1_
- $a van den Berg, Hendrick $u Product Development Scientific Support Department, European Medicines Agency, Canary Wharf, London, UK.
- 700 1_
- $a Uttenreuther-Fischer, Martina $u Boehringer Ingelheim, Germany.
- 700 1_
- $a Witt, Olaf $u Clinical Cooperation Unit Pediatric Oncology (G340), German Cancer Research Center (DKFZ), Heidelberg, Germany.
- 700 1_
- $a Norga, Koen $u Paediatric Haematology/Oncology Unit, Antwerp University Hospital, Antwerp University, Belgium.
- 700 1_
- $a Vassal, Gilles $u Department of Clinical Research, Institut Gustave Roussy, Paris-Sud University, Paris, France.
- 700 1_
- $a ,
- 773 0_
- $w MED00009626 $t European journal of cancer (Oxford, England 1990) $x 1879-0852 $g Roč. 62, č. - (2016), s. 124-31
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27258969 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171025115636 $b ABA008
- 999 __
- $a ok $b bmc $g 1255282 $s 992716
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 62 $c - $d 124-31 $e 20160531 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20171025
